Insigniam B.I.T.s

Biotech Breakthrough: How eGenesis is Pioneering a New Scientific Frontier

Insigniam

Following the world’s first successful xenotransplant of a genetically engineered pig kidney into a living human patient, eGenesis—a biotech company committed to transforming the treatment of organ failure—is closer than ever to accomplishing its ultimate mission: solving the global organ transplant crisis.

To get a sense of what it took to achieve this historic breakthrough, IQ spoke with eGenesis CEO, Dr. Mike Curtis, and Chief People Officer, Elizabeth Roberts, about the incredible milestone and what's next on the company's horizon.